4 research outputs found
Covid-19 pandemisinin günlük üroloji pratiğine etkisi: İlk 3 aylık dönemdeki çok merkezli çalışmamız(Impact of the Covid-19 pandemic on daily urology practice: First 3 months multicenter results in Istanbul)
Covid-19 pandemisinin günlük üroloji pratiğine etkisi: İlk 3 aylık dönemdeki çok merkezli çalışmamız
The clinical impact of the COVID-19 pandemic on daily urological practice: First 3 month multicenter results from Istanbul.
Background/aim: The aim of this paper was to determine the general tendencies of urology patients and effect of COVID-19 pandemic on daily urological practice at tertiary centers located in the most affected area in Turkey
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference